



Correction: New diagnostic criteria (2023) for slowly progressive type 1 diabetes (SPIDDM): Report from Committee on Type 1 Diabetes in Japan Diabetes Society (English version)

Akira Shimada¹ · Eiji Kawasaki² · Norio Abiru³ · Takuya Awata⁴ · Yoichi Oikawa¹ · Haruhiko Osawa⁵ · Hiroshi Kajio⁶ · Junji Kozawa⁷ · Kazuma Takahashi⁸ · Daisuke Chujo⁹ · Shinsuke Noso¹⁰ · Tomoyasu Fukui¹¹ · Junnosuke Miura¹² · Kazuki Yasuda¹³ · Hisafumi Yasuda¹⁴ · Akihisa Imagawa¹⁵ · Hiroshi Ikegami¹⁰

© The Japan Diabetes Society 2024

Correction: Diabetology International (2023) 15:1–4
<https://doi.org/10.1007/s13340-023-00679-1>

In the original publication of the article, under the discussion section, in the following paragraph “Moreover, regarding the concept of ...”, “for” should be replaced with “at” in the third point. The correct sentence should read as follows “(3) insulin treatment required at more than 6 months after the diagnosis of diabetes.”

Similarly, under the same section, in the following paragraph “According to the IDS diagnostic criteria for...”, “for”

should be replaced with “at” in a few occurrences. The correct sentences should read as follows “According to the IDS diagnostic criteria for LADA, insulin treatment is required at more than 6 months [4] after the diagnosis of diabetes. However, considering the diagnostic criteria of AT1D [6], we described the necessity of insulin treatment at more than 3 months in the new criteria of SPIDDM (2023) and added a comment on the necessity of insulin treatment at more than 6 months after diagnosis of diabetes in typical cases.”

Finally, in Table 1, on third factor, “for” should be replaced with “at”. The correct sentence should read as follows “(3) Gradual reduction in insulin secretion overtime, requirement of insulin treatment at more than 3 monthsb after diagnosis of diabetes, and severe endogenous insulin deficiency

The original article can be found online at <https://doi.org/10.1007/s13340-023-00679-1>.

✉ Akira Shimada
asmd@saitama-med.ac.jp

- ¹ Department of Endocrinology and Diabetes, School of Medicine, Saitama Medical University, 38 Morohongo, Moroyama, Iruma, Saitama, Japan
- ² Diabetes Center, Shin-Koga Hospital, Fukuoka, Japan
- ³ Midori Clinic, Nagasaki, Japan
- ⁴ Pancreatic Islet Cell Transplantation Center, National Center for Global Health and Medicine, Tokyo, Japan
- ⁵ Department of Diabetes and Molecular Genetics, Ehime University Graduate School of Medicine, Ehime, Japan
- ⁶ Department of Diabetes, Endocrinology and Metabolism, Center Hospital of the National Center for Global Health and Medicine, Tokyo, Japan
- ⁷ Department of Diabetes Care Medicine, Graduate School of Medicine, Osaka University, Osaka, Japan
- ⁸ Department of Basic Nursing Science, School of Nursing, Iwate Prefectural University, Iwate, Japan

- ⁹ Center for Clinical Research, Toyama University Hospital, Toyama, Japan
- ¹⁰ Department of Endocrinology, Metabolism and Diabetes, Kindai University Faculty of Medicine, Osaka, Japan
- ¹¹ Department of Medicine, Division of Diabetes, Metabolism and Endocrinology, Showa University School of Medicine, Tokyo, Japan
- ¹² Division of Diabetology and Metabolism, Department of Internal Medicine, Tokyo Women's Medical University School of Medicine, Tokyo, Japan
- ¹³ Department of Diabetes, Endocrinology and Metabolism, Kyorin University School of Medicine, Tokyo, Japan
- ¹⁴ Division of Health Sciences, Department of Public Health, Kobe University Graduate School of Health Sciences, Hyogo, Japan
- ¹⁵ Department of Internal Medicine (I), Faculty of Medicine, Osaka Medical and Pharmaceutical University, Osaka, Japan

(fasting serum C-peptide immunoreactivity <0.6 ng/mL) at the last observed time point”.

Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.